Our Science

Targeting the Biology of Aging

Aging is the biggest modifiable risk factor for most chronic diseases and is caused by a discrete number of biological mechanisms that can be targeted therapeutically.

Life Biosciences healthspan

Source: Global Burden of Disease Collaborative Network

A New Approach

Life Biosciences is pursuing indication areas where aging biology has a clear link to disease pathogenesis. We prioritize diseases where there are limited or no available treatment options approved today. We are currently developing therapeutics targeting two biological mechanisms that contribute to aging: Epigenetic alterations and loss of proteostasis.

Source: Lopez-Otin C et al. Cell (2013)


Areas of Focus

Our platforms are based on science in-licensed from world-leading researchers. These platforms have the potential to reverse and prevent multiple aging-related diseases, each with critical unmet medical needs.

Partial Epigenetic Reprogramming Platform
Developing therapies that induce the expression of three Yamanaka factors (OCT4, SOX2 and KLF4 [OSK]) that reprogram the epigenome. Gene therapy candidates have demonstrated safety and efficacy in preclinical mouse models for nerve crush and glaucoma and in a preclinical non-human primate model for non-arteritic anterior ischemic optic neuropathy (NAION).

Chaperone-Mediated Autophagy Platform
Developing small molecule activators of chaperone-mediated autophagy that decrease the accumulation of aggregated proteins and have demonstrated safety and efficacy in preclinical models of neurodegeneration and retinal degeneration.